Clinical Trial Update: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Brentuximab Vedotin to physician's choice in CD30-positive cutaneous T-cell lymphoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Anaplastic Large Cell Lymphoma
• Cutaneous T-cell Lymphoma
• Mycosis Fungoides

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides | Phase 3 | Status: COMPLETED | Results posted: 2018-03-16